Search Result

Isoforms Recommended:	Na_v1.7

Results for "

Nav1.7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Apoptosis (2) Arrestin (2) Calcium Channel (4) Cytochrome P450 (1) Drug Derivative (1) ERK (2) Histamine Receptor (1) iGluR (2) Interleukin Related (2) Melatonin Receptor (2) Neurotensin Receptor (2) NF-κB (2) P2X Receptor (2) p38 MAPK (2) Potassium Channel (5) Reference Standards (7) Small Interfering RNA (siRNA) (3) Sodium Channel (100) TNF Receptor (2) TRP Channel (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Inflammation/Immunology (14) Neurological Disease (94)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

108

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6691

Veratridine 4 Publications Verification 3-Veratroylveracevine	Sodium Channel	Neurological Disease
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-125079

DSP-2230 ANP-230	Sodium Channel	Cardiovascular Disease Neurological Disease
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC₅₀s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .

HY-12883

PF 05089771 4 Publications Verification	Sodium Channel	Neurological Disease
PF 05089771 is a potent, orally active and selective arylsulfonamide *Na_v1.7* inhibitor, with IC₅₀ values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNa_v1.7, cynNa_v1.7, dogNa_v1.7, ratNa_v1.7, and musNa_v1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy .

HY-N0478

Neoline 1 Publications Verification Bullatine B	Others	Neurological Disease
Neoline (Bullatine B) is the active ingredient of the active ingredient (PA), which can be used to cure the disease. Neoline Flow Suppression Nav1.7 Electrical Flow Control (VGSC), improve diabetes mechanical pain sensitivity. Neoline has a list of compounds that can be used, research on its use, and the quality of its processing during processing in pain .

HY-118952A

PF-06456384 trihydrochloride	Sodium Channel	Neurological Disease
PF-06456384 trihydrochloride is an extremely potent and selective Na_v1.7 sodium channel blocker (IC₅₀: 0.01 nM for hNaV1.7; 75 nM for rNaV1.7; <0.1 nM for mNaV1.7). PF-06456384 trihydrochloride shows no significant analgesic efficacy in the mouse Formalin pain model .

HY-12796A

Raxatrigine hydrochloride Vixotrigine hydrochloride; GSK-1014802 hydrochloride; CNV1014802 hydrochloride	Sodium Channel	Neurological Disease
Raxatrigine hydrochloride (GSK-1014802 hydrochloride) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

HY-12796

Raxatrigine Vixotrigine; GSK-1014802; CNV1014802	Sodium Channel	Neurological Disease
Raxatrigine (GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.

HY-114237

GDC-0276	Sodium Channel	Neurological Disease
GDC-0276 is a potent, selective, reversible and orally active *NaV1.7* inhibitor with an IC₅₀ value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects .

HY-139081

GDC-0310	Sodium Channel	Neurological Disease
GDC-0310 is a selective acyl-sulfonamide *Na_v1.7* inhibitor, with an IC₅₀ of 0.6 nM for hNa_v1.7 .

HY-13985

Nav1.7 inhibitor	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent *Nav1.7* inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain, including acute pain, inflammatory pain and/or neuropathic pain .

HY-16723

Funapide TV 45070; XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC₅₀ values ??of 84 nM and 54 nM for *Nav1.5* and *Nav1.7*, respectively. Funapide has analgesic effects .

HY-119934

NaV1.7 inhibitor-1	Sodium Channel	Neurological Disease
NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC₅₀ of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 .

HY-112279

GNE-131	Sodium Channel	Neurological Disease
GNE-131 is a potent and selective inhibitor of human sodium channel *NaV1.7, with an IC₅₀* of 3 nM.

HY-107405

TC-N 1752	Sodium Channel	Neurological Disease
TC-N 1752 is a potent and orally active inhibitor of *Nav1.7, with IC₅₀s of 0.17 μM, 0.3 μM, 0.4 μM, 1.1 μM and 2.2 μM at hNav1.7, hNav1.3, hNav1.4, hNaV1.5* and rNav1.8, respectively. TC-N 1752 also inhibits tetrodotoxin-sensitive sodium channels. TC-N 1752 shows analgesic efficacy in the Formalin model of pain .

HY-19958

XEN907	Sodium Channel	Neurological Disease
XEN907 is a potent and spirooxindole blocker of *Na_V1.7, with an IC₅₀* of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain .

HY-12811

PF-04856264 1 Publications Verification	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective *Nav1.7* inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-145169

AZ194	Sodium Channel	Neurological Disease
AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of *NaV1.7* (IC₅₀=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects .

HY-101789

Nav1.7-IN-3	Sodium Channel	Neurological Disease
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC₅₀ of 8 nM. Pain relief. Limited CNS penetration .

HY-131182

DS-1971a 1 Publications Verification	Sodium Channel	Neurological Disease
DS-1971a is a potent, selective, and orally active *NaV1.7* inhibitor, with IC₅₀s of 22.8 and 59.4 nM for hNaV1.7 and mNaV1.7, respectively. DS-1971a exerts analgesic effects .

HY-N1847

3'-Methoxydaidzein	Sodium Channel	Neurological Disease
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .

HY-164795

SBI-810	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of *Nav1.7* and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders .

HY-164795A

SBI-810 hydrochloride	Neurotensin Receptor Arrestin iGluR ERK Sodium Channel	Neurological Disease
SBI-810 hydrochloride is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 hydrochloride promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 hydrochloride inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of *Nav1.7* and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 hydrochloride effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 hydrochloride is applicable to research related to multiple pain disorders .

HY-131870

GX-201	Sodium Channel	Inflammation/Immunology
GX-201 is a selective *Na_V1.7* inhibitor, with an IC₅₀ of <3.2 nM for hNa_V1.7 .

HY-156596

Aneratrigine	Sodium Channel	Neurological Disease
Aneratrigine is a selective *Nav1.7* inhibitor with an IC₅₀ of 19 nM. Aneratrigine is applicable for pain-related research .

HY-122001

PF-05186462	Sodium Channel	Neurological Disease
PF-05186462 is a potent and selective inhibitor of *human Nav1.7* voltage-dependent sodium channel, with an IC₅₀** of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .

HY-146069

ABBV-318	Sodium Channel	Neurological Disease
ABBV-318 is a potent **Nav1.7/ Nav1.8 blocker, with IC₅₀s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8**, respectively. ABBV-318 can be used for the research of pain .

HY-178494

Nav1.7-IN-19	Sodium Channel Potassium Channel	Neurological Disease
Nav1.7-IN-19 is a potent, selective and orally active *Nav1.7* inhibitor with an IC₅₀ of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease .

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-178281

E0199	Potassium Channel Sodium Channel	Neurological Disease
E0199 is a novel potent dual-target *K_V7/Na_V* modulator that activates the K_V7 channel (K_V7.2/7.3 (EC₅₀ = 12.78 nM), K_V7.2 (EC₅₀ = 0.50 μM), and K_V7.5 (EC₅₀ = 27.14 nM) channels) while simultaneously blocks the Na_V1.7 (IC₅₀ = 0.52 μM), Na_V1.8 (IC₅₀ = 0.24 μM), and Na_V1.9 (IC₅₀ = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research .

HY-133910

Lu AE98134 1 Publications Verification	Sodium Channel	Neurological Disease
Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Na_v1.1 channels positive modulator. Lu AE98134 also increases the activity of Na_v1.2 and Na_v1.5 channels but not of Na_v1.4, Na_v1.6 and Na_v1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Na_v1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .

HY-19366

Nav1.7-IN-2	Sodium Channel	Neurological Disease
Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

HY-103623

PF-05241328	Sodium Channel	Neurological Disease
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels *(Nav1.7), with an IC₅₀* of 31 nM.

HY-100727

AM-2099 1 Publications Verification	Sodium Channel	Neurological Disease
AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel *Nav1.7* with an IC₅₀ of 0.16 μM for human Nav1.7.

HY-P1073

ProTx-I	Calcium Channel Potassium Channel Sodium Channel TRP Channel	Neurological Disease Cancer
ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as *NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC₅₀* values of ProTx-I against human *NaV1.7, NaV1.2, NaV1.6, and NaV1.5* are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba ²⁺ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) .

HY-108425B

(Rac)-AMG8379 (Rac)-AMG8380	Sodium Channel	Neurological Disease
(Rac)-AMG8379 ((Rac)-AMG8380) is a racemate of AMG8379. AMG8379 is a potent, orally active and selective sulfonamide antagonist of NaV1.7, with IC₅₀s of 8.5 and 18.6 nM for hNaV1.7 and mNaV1.7, respectively .

HY-105285

Piromelatine 2 Publications Verification Neu-P11	Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel	Neurological Disease
Piromelatine (Neu-P11) is a melatonin MT₁/MT₂ receptor agonist, serotonin 5-HT_1A/5-HT_1D agonist, and serotonin 5-HT_2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities .

HY-118952

PF-06456384	Sodium Channel	Neurological Disease
PF-06456384 is a highly potent and selective *Na_V1.7* inhibitor with an IC₅₀ of 0.01 nM. PF-06456384 has the potential for formalin pain model research .

HY-12883A

PF-05198007	Sodium Channel	Neurological Disease
PF-05198007 is a potent, orally active and selective arylsulfonamide *Na_v1.7* inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .

HY-16723A

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel *Nav1.7, Nav1.8* and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-117714

AZD-3161	Sodium Channel	Neurological Disease
AZD-3161 is a potent and selective blocker of Na_V1.7 channel, with a pIC₅₀ of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5786

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-123825

GX-674	Sodium Channel	Cardiovascular Disease Neurological Disease
GX-674 is a potent, state-dependent, isoform-selective voltage-gated sodium channel 1.7 (Nav1.7) antagonist with an IC₅₀ of 0.1 nM at -40 mV .

HY-123414

GX-936 PF-05196233	Sodium Channel	Neurological Disease
GX-936 (PF-05196233), a potent and *Nav1.7*-subtype selective inhibitor, binds to the activated state of voltage-sensor domain IV (VSD4) .

HY-P10234A

Poneratoxin acetate 3 Publications Verification	Sodium Channel	Neurological Disease
Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-108425

AMG8379	Sodium Channel	Neurological Disease
AMG8379 is a potent, orally active and selective sulfonamide antagonist of the voltage-gated sodium channel NaV1.7, with IC₅₀s of 8.5 and 18.6 nM for hNaV1.7 and mNaV1.7, respectively. AMG8379 potently and reversibly blocks endogenous Tetrodotoxin (TTX)-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC₅₀ of 3.1 nM .

HY-P11045

JNJ63955918	Sodium Channel	Neurological Disease
JNJ63955918 is a potent, highly selective, blocked-state *Nav1.7* blocking peptide with an IC₅₀ of 8.0 nM. JNJ63955918 can be used in pain research .

HY-116194

NaV1.7 blocker-801	Sodium Channel	Neurological Disease
NaV1.7 blocker-801 is a NaV1.7 channel blocker that can be used in the study of neurological diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P1073

ProTx-I	Calcium Channel Potassium Channel Sodium Channel TRP Channel	Neurological Disease Cancer
ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as *NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC₅₀* values of ProTx-I against human *NaV1.7, NaV1.2, NaV1.6, and NaV1.5* are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba ²⁺ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5786

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P10234A

Poneratoxin acetate 3 Publications Verification	Sodium Channel	Neurological Disease
Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-P11045

JNJ63955918	Sodium Channel	Neurological Disease
JNJ63955918 is a potent, highly selective, blocked-state *Nav1.7* blocking peptide with an IC₅₀ of 8.0 nM. JNJ63955918 can be used in pain research .

HY-P5809

Pe1b μ-TrTx-Pe1b	Sodium Channel	Neurological Disease
Pe1b (μ-TrTx-Pe1b) is a selective *Na_v1.7* inhibitor with an IC₅₀ of 167 nM .

HY-P5160A

Phlotoxin-1 TFA PhlTx1 TFA	Sodium Channel	Neurological Disease
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel .

HY-P5781

δ-Theraphotoxin-Hm1b	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of *NaV1.1* but have no effect on NaV1.7 .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P1681A

GpTx-1 TFA	Sodium Channel	Neurological Disease
GpTx-1 TFA is a peptide-based *Na_V1.7* sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 TFA demonstrates potent inhibitory activity against the *Na_V1.7* channel with an IC₅₀ value of 10 nM, while exhibiting excellent selectivity for *Na_V1.4* (IC₅₀ = 0.301 μM) and *Na_V1.5* (IC₅₀ = 4.20 μM), showing >20-fold and >950-fold selectivity respectively .

HY-P1681

GpTx-1	Sodium Channel	Neurological Disease
GpTx-1 is a peptide-based *Na_V1.7* sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 demonstrates potent inhibitory activity against the *Na_V1.7* channel with an IC₅₀ value of 10 nM, while exhibiting excellent selectivity for *Na_V1.4* (IC₅₀ = 0.301 μM) and *Na_V1.5* (IC₅₀ = 4.20 μM), showing >20-fold and >950-fold selectivity respectively .

HY-P10234

Poneratoxin	Sodium Channel	Neurological Disease
Poneratoxin is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and hERG1 channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively .

HY-P5900

m3-Huwentoxin IV m3-HwTx-IV	Sodium Channel	Neurological Disease
m3-Huwentoxin IV (m3-HwTx-IV) is a potent *Na_V* inhibitor with IC₅₀s of 3.3, 6.8, 7.2, 8.4, 11.9 and 369 nM against hNa_V1.7, hNa_V1.6, hNa_V1.3, hNa_V1.1, hNa_V1.2 and hNa_V1.4, respectively in QPatch assay. m3-Huwentoxin IV dose-dependently suppresses spontaneous pain induced by the Na_V1.7 activator OD1 in a rodent pain model .

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* .

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

HY-P5160

Phlotoxin-1 PhlTx1	Sodium Channel	Neurological Disease
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel .

HY-P5813

Cd1a β-TRTX-cd1a; β-Theraphotoxin-cd1a	Calcium Channel	Neurological Disease
Cd1a is a β-toxin derived from the African spider Ceratogyrus darlingi. Cd1a can regulate calcium ion channels. Cd1a inhibits human calcium ion channels (Ca_v2.2)(IC₅₀2.6 μM) and mouse sodium ion channels (Na_v1.7). Cd1a can be used in the development of peripheral pain treatment drugs .

HY-P5153

ProTx-III μ-TRTX-Tp1a	Sodium Channel	Neurological Disease
ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel *Na_v1.7, with an IC₅₀* of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel, with IC₅₀s of 0.63 μM, 0.23 μM, 0.77 μM, 1.29 μM, 0.63 μM and 0.37 μM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively . GrTx1 can be used for neurological disease research .

HY-P5790

μ-TRTX-Hd1a	Sodium Channel	Neurological Disease
μ-TRTX-Hd1a, a spider venom, is a selective *NaV 1.7* inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990503

*Anti-SCN9a/Nav1.7* Antibody**	Sodium Channel	Inflammation/Immunology
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting *SCN9a/Nav1.7. Anti-SCN9a/Nav1.7* Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703462

	*VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep)* NENA	Human	HEK293
	VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep) is the recombinant human-derived VSD4-NaV1.7-NaVPas, expressed by HEK293 , with Strep, Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Nav1.7

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Oligonucleotides

Natural
Products